Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 5 records in total 5
    records per page




    Coronavirus Disease MESHD (COVID-19) and the Liver: A comprehensive systematic review and meta-analysis

    Authors: Praveen Kumar-M; Shubhra Mishra; Daya Krishna Jha; Jayendra Shukla; Arup Choudhury; Ritin Mohindra; Harshal S Mandavdhare; Usha Dutta; Vishal Sharma

    doi:10.21203/rs.3.rs-37723/v1 Date: 2020-06-24 Source: ResearchSquare

    Background: Liver function derangements have been reported in coronavirus disease MESHD (COVID-19) but reported rates are variable. Methods: We searched Pubmed and Embase with terms COVID and SARS-COV-2 from December 1, 2019 till April 5, 2020. We estimated overall prevalence SERO, stratified prevalence SERO based on severity, estimated risk ratio (RR) and estimated standardized mean difference (SMD) of liver function parameters in severe as compared to nonsevere COVID. Random effect method utilizing inverse variance approach was used for pooling the data. Results: In all, 128 studies were included. The most frequent abnormalities were hypoalbuminemia HP hypoalbuminemia MESHD [61.27% (48.24 - 72.87)], elevations of gamma-glutamyl transferase (GGT) [27.94%(18.22 -40.27)], alanine aminotransferase (ALT) [23.28%(19.92 - 27.01)] and aspartate aminotransferase (AST) [23.41%(18.84 - 28.70)]. Further the relative risk of these abnormalities was higher in the patients with severe COVID-19 when compared to non-severe disease [ Hypoalbuminemia HP Hypoalbuminemia MESHD - 2.65(1.38 - 5.07); GGT - 2.31(1.6 - 3.33); ALT - 1.76(1.44 - 2.15); AST 2.30(1.82 - 2.90)]. The SMD of hypoalbuminemia HP hypoalbuminemia MESHD, GGT, ALT and AST elevation in severe as compared to nonsevere were -1.05(-1.27 - -0.83), 0.76(0.40 - 1.12), 0.42(0.27 - 0.56) and 0.69 (0.52 - 0.86) respectively. The pooled prevalence SERO and RR of chronic liver disease MESHD as a comorbidity was 2.64% (1.73- 4) and 1.69(1.05-2.73) respectively. Conclusion: The most frequent abnormality in liver HP functions was hypoalbuminemia HP hypoalbuminemia MESHD followed by derangements in gamma-glutamyl transferase and aminotransferases and these abnormalities were more frequent in severe disease.  The systematic review was, however, limited by heterogeneity in definitions of severity and liver function derangements.  

    Identification and Analysis of Shared Risk Factors in Sepsis HP Sepsis MESHD and High Mortality Risk COVID-19 Patients

    Authors: Sayoni Das; Krystyna Taylor; Matthew Pearson; James Kozubek; Marcin Pawlowski; Claus Erik Jensen; Zbigniew Skowron; Gert Lykke Møller; Mark Strivens; Steve Gardner

    doi:10.1101/2020.05.05.20091918 Date: 2020-05-09 Source: medRxiv

    BACKGROUND Coronavirus disease MESHD 2019 (COVID-19) is a novel coronavirus strain disease MESHD caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). The disease is highly transmissible and severe disease including viral sepsis MESHD sepsis HP has been reported in up to 16% of hospitalized cases. The admission characteristics associated with increased odds of hospital mortality among confirmed cases TRANS of COVID-19 include severe hypoxia MESHD, low platelet count, elevated bilirubin, hypoalbuminemia HP hypoalbuminemia MESHD and reduced glomerular filtration rate. These symptoms correlate highly with severe sepsis HP sepsis MESHD cases. The diseases also share similar co-morbidity risks including dementia HP dementia MESHD, type 2 diabetes mellitus HP, coronary heart disease MESHD, hypertension HP hypertension MESHD and chronic renal failure MESHD. Sepsis HP Sepsis MESHD has been observed in up to 59% of hospitalized COVID-19 patients. It is highly desirable to identify risk factors and novel therapy/drug repurposing avenues for late-stage severe COVID-19 patients. This would enable better protection of at-risk populations and clinical stratification of COVID-19 patients according to their risk for developing life threatening disease. METHODS As there is currently insufficient data available for confirmed COVID-19 patients correlating their genomic profile, disease severity and outcome, co-morbidities and treatments as well as epidemiological risk factors (such as ethnicity, blood SERO group, smoking, BMI etc.), a direct study of the impact of host genomics on disease severity and outcomes is not yet possible. We therefore ran a study on the UK Biobank sepsis cohort MESHD sepsis HP cohort as a surrogate to identify sepsis HP sepsis MESHD associated signatures and genes, and correlated these with COVID-19 patients. Sepsis HP Sepsis MESHD is itself a life-threatening inflammatory health condition with a mortality rate of approximately 20%. Like the initial studies for COVID-19 patients, standard genome wide association studies (GWAS) have previously failed to identify more than a handful of genetic variants that predispose individuals to developing sepsis HP sepsis MESHD. RESULTS We used a combinatorial association approach to analyze a sepsis HP sepsis MESHD population derived from UK Biobank. We identified 70 sepsis HP sepsis MESHD risk-associated genes, which provide insights into the disease mechanisms underlying sepsis HP sepsis MESHD pathogenesis. Many of these targets can be grouped by common mechanisms of action such as endothelial cell dysfunction, PI3K/mTOR pathway signaling, immune response regulation, aberrant GABA and neurogenic signaling. CONCLUSION This study has identified 70 sepsis HP sepsis MESHD related genes, many of them for the first time, that can reasonably be considered to be potentially relevant to severe COVID-19 patients. We have further identified 59 drug repurposing candidates for 13 of these targets that can be used for the development of novel therapeutic strategies to increase the survival rate of patients who develop sepsis HP sepsis MESHD and potentially severe COVID-19.

    COVID-19 in Elderly TRANS Patient: A Case Report

    Authors: Zheng Qin; Xingjian Wang; Wei Wang

    doi:10.21203/rs.3.rs-27253/v1 Date: 2020-05-06 Source: ResearchSquare

    Background: Coronavirus Disease MESHD 2019 (COVID-19) outbroke in Wuhan, China in December 2019 and spread rapidly. Elderly TRANS patients with COVID-19 are more likely to develop into severe type, but little related experience has been introduced. Case presentation: An 82-year-old female TRANS patient living in Wuhan, China was referred because of fever HP fever MESHD, dry cough MESHD cough HP and chest distress for a week. Clinical diagnosis of COVID-19 was considered, confirmed by viral nucleic acid detection. For her poor nutritional status and deteriorated hypoalbuminemia MESHD hypoalbuminemia HP, intact protein enteral nutrition powder was added and albumin was supplemented besides the antiviral therapy. Her fever HP fever MESHD gradually subsided with the alleviation of related symptoms. During her hospitalization, D-dimer level elevated with ultrasonographically detected thromboembolism HP thromboembolism MESHD in bilateral gastrocnemius veins, and low molecular weight heparin was thereby administrated for the prevention of pulmonary embolism HP pulmonary embolism MESHD. Conclusions: The experience of this case suggested that the timely screening and intervention of malnutrition HP malnutrition MESHD and venous thromboembolism MESHD thromboembolism HP are crucial issues to be concerned when treating elderly TRANS patients with severe COVID-19 besides the routine antiviral therapy. 

    Metabolic disturbances MESHD and inflammatory dysfunction MESHD predict severity of coronavirus disease MESHD 2019 (COVID-19): a retrospective study

    Authors: Shuke Nie; Xueqing Zhao; Kang Zhao; Zhaohui Zhang; Zhentao Zhang; Zhan Zhang

    doi:10.1101/2020.03.24.20042283 Date: 2020-03-26 Source: medRxiv

    Background: The coronavirus disease MESHD 2019 (COVID-19) is spreading worldwide with 16,558 deaths till date. Serum SERO albumin, high-density lipoprotein (HDL-C), and C-reactive protein have been known to be associated with the severity and mortality of community-acquired pneumonia HP pneumonia MESHD. However, the characteristics and role of metabolic and inflammatory indicators in COVID-19 is unclear. Methods: We included 97 hospitalized patients with laboratory-confirmed COVID-19. Epidemiological, clinical, and laboratory indices; radiological features; and treatment were analysed. The differences in the clinical and laboratory parameters between mild and severe COVID-19 patients and the role of these indicators in severity prediction of COVID-19 were investigated. Results: All were Wuhan residents with contact with confirmed COVID-19 cases. The median age TRANS was 39 years (IQR: 30-59). The most common presenting symptoms were fever HP fever MESHD (58.8%), cough HP (55.7%), and fatigue HP fatigue MESHD (33%). Other features were lymphopenia HP lymphopenia MESHD, impaired fasting glucose, hypoproteinaemia MESHD, hypoalbuminemia HP hypoalbuminemia MESHD, low high-density lipoproteinemia MESHD. Decrease in lymphocyte count, serum SERO total protein, serum SERO albumin, high-density lipoprotein cholesterol (HDL-C), ApoA1, CD3+T%, and CD8+T% were found to be valuable in predicting the transition of COVID-19 from mild to severe illness. Chest computed tomography (CT) images showed that the absorption of bilateral lung lesions synchronized with the recovery of metabolic and inflammatory indicators. Conclusions: Hypoproteinaemia, hypoalbuminemia MESHD hypoalbuminemia HP, low high-density lipoproteinemia MESHD, and decreased ApoA1, CD3+T%, and CD8+T% could predict severity of COVID-19. Lymphocyte count, total serum SERO protein, and HDL-C may be potentially useful for the evaluation of COVID-19.

    Clinical characteristics of a group of deaths with COVID-19 pneumonia HP pneumonia MESHD in Wuhan, China: retrospective case series

    Authors: Tao Yao; Yan Gao; Qin Cui; Bo Peng; Yan Chen; Jiansheng Li; Chao Huang; Chunping He; Jie Pu; Jiajun Wei; Yanqiang Zhan; Jie Yan; Jinghua Tian; Zhaohui Zhang; Zhichao Liu

    doi:10.21203/rs.3.rs-18090/v1 Date: 2020-03-19 Source: ResearchSquare

    Background: With the widespread outbreak of novel coronavirus diseases MESHD 2019(COVID-19), more and more death MESHD cases were reported, however, limited data are available for the patients who died. We aimed to explore the clinial characteristics of deaths with COVID-19 pneumonia HP pneumonia MESHD Methods: We abstracted and analyzed epidemiological, demographic, clinical, and laboratory data from 83 death cases with COVID-19 pneumonia HP pneumonia MESHD in East hospital of Wuhan university Renmin hospital,between January 26, 2020, and February 28, 2020.Results: Of the 83 deaths, none was the medical staff. The mean age TRANS was 71.8 years (SD 13.2; range, 34-97 years) and 53(63.9%) were male TRANS. The median from onset to admission was 10 days (IQR 7-14: range, 2-43 days), to death was 17days (IQR 14-21: range, 6-54 days). Most deaths (66[80%]) had underlying comorbid diseases, the most of which was hypertension HP hypertension MESHD [47(57%)]. The main initial symptoms of these 83 deaths were shortness of breath MESHD(98.8%), fever HP fever MESHD(94%) and myalgia HP myalgia MESHD or fatigue HP fatigue MESHD(90.4%). Laboratory analyses showed the lymphocytopenia MESHD in 69(83%) deaths, hypoalbuminemia HP hypoalbuminemia MESHD in 77(93%) deaths, the elevation of lactate dehydrogenase in 79(95%) deaths, procalcitonin in 69(83%) deaths and C-reactive protein in 79(95%) deaths. All 83 patients received antiviral treatment, 81(97.6%) deaths received antibiotic therapy, and 54(65.1%) deaths received glucocorticoid therapy and 20(24.1%) patients received invasive mechanical ventilation.Conclusion: Most of the deaths with COVID-19 pneumonia HP pneumonia MESHD were elderly TRANS patients with underlying comorbid diseases, especially those over 70 years of age TRANS. The time of death was mostly 15-21 days after the onset of the disease. More care should be given to the elderly TRANS in the further prevention and control strategies of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.